Trial Profile
Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Vorolanib (Primary)
- Indications Carcinoma; Malignant thymoma; Non-small cell lung cancer; Small cell lung cancer; Thoracic neoplasms
- Focus Adverse reactions; Therapeutic Use
- 08 Aug 2023 Number of treatment arms are increased from 1 to 6 by the addition of 5 more experimental arms (in the dose expansion segment) namely- Non Small-Cell-Lung Cancer Acquired Resistance, Non Small-Cell-Lung Cancer Naive, Non Small-Cell-Lung Cancer Primary Refractory, Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy and Thymic Carcinoma.
- 08 Aug 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 08 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.